Articles from Rivus Pharmaceuticals, Inc.

Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek®

First data from Rivus’ preclinical CMA pipeline showing potential as monotherapy and in combination with GLP-1s

By Rivus Pharmaceuticals, Inc. · Via GlobeNewswire · November 4, 2025